Pfizer statement regarding CDC’s ACIP discussion of Prevnar 13®
22 February 2012 | By Pfizer
Pfizer believes Prevnar 13 should be recommended for all adults 50 years of age and older...
List view / Grid view
News
Boehringer Ingelheim and Xencor enter a collaboration agreement
21 February 2012 | By Boehringer Ingelheim
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life...
European Commission approves CAPRELSA® (vandetanib) for patients with advanced medullary thyroid cancer
21 February 2012 | By AstraZeneca
Marketing authorisation for CAPRELSA® (vandetanib) granted...
Roche’s Zelboraf receives EU approval
20 February 2012 | By Roche
First and only personalized skin cancer medicine allows people with BRAF V600 mutation-positive metastatic melanoma to live significantly longer...
Plexxikon announces European approval of Zelboraf®
20 February 2012 | By Daiichi Sankyo
The European Commission has approved Zelboraf® (vemurafenib)...
Bristol-Myers Squibb Foundation announces grants focused on prevention, diagnosis & care of Hepatitis B and Hepatitis C in Asia
18 February 2012 | By Bristol-Myers Squibb
Three new grants awarded...
Gilead announces data for genotype 1 null responder hepatitis C patients enrolled in ELECTRON study
17 February 2012 | By Gilead Sciences
Viral relapse seen post treatment with GS-7977 plus ribavirin...
Novartis to revise product information in the European Union for high blood pressure drug Rasilez®
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
GSK receives positive opinion in Europe from the CHMP for Nimenrix®
17 February 2012 | By GlaxoSmithKline
The EMA's CHMP has issued a positive opinion recommending marketing authorisation for Nimenrix® (MenACWY-TT)...
CHMP recommends approval of BYETTA® for use with basal insulin
17 February 2012 | By Eli Lilly and Company
Patients in pivotal study achieved better glycemic control without weight gain...
Abbott receives positive opinion for HUMIRA® in Ulcerative Colitis from EMA’s CHMP
17 February 2012 | By Abbott
Positive opinion based on supporting data from two Phase III clinical studies...
Pfizer and Hisun announce progress on potential joint venture to increase access to high quality branded generic medicines
17 February 2012 | By Pfizer
The framework agreement builds upon the MOU, and is an important milestone in the formation of a joint venture between the two companies...
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)
16 February 2012 | By GlaxoSmithKline
GlaxoSmithKline has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib)...
Stuart Grant appointed Patheon’s Executive Vice President, Chief Financial Officer
Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Stuart Grant has been appointed Patheon's Executive Vice President, Chief Financial Officer. Mr. Grant comes to Patheon following an accomplished career with increasing levels of responsibility in finance for several…
FDA accepts Pfizer’s New Drug Application for Tafamidis Meglumine
15 February 2012 | By Pfizer
A novel, investigational treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)...
